

- 2 **Recidivující infekce horních cest dýchacích – podpora imunity**  
doc. MUDr. Jaromír Bystroň, CSc. Oddělení alergologie a klinické imunologie FN, Olomouc
- 2 **Biologická léčba astmatu – nové cíle a perspektivy**  
prof. MUDr. Ilja Stříž, CSc. Pracoviště klinické a transplantační imunologie IKEM, Praha
- 3 **Novinky v léčbě hypertenze**  
prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika, LF MU a FN u sv. Anny, Brno  
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno, Brno-Bohunice
- 3 **Metabolický syndrom v roce 2016**  
prof. MUDr. Milan Kvapil, CSc., MBA Interní klinika FN Motol a 2. LF UK, Praha
- 3 **Klinická farmakologie přímých perorálních antikoagulantů**  
doc. MUDr. Karel Urbánek, Ph.D. Ústav farmakologie LF UP a FN, Olomouc
- 4 **Edoxaban – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 4 **Inovativní přístupy v léčbě roztroušené sklerózy**  
MUDr. Marek Peterka Neurologická klinika, LF UK a FN, Plzeň
- 5 **Léčba psoriatické artritidy – nové pohledy**  
MUDr. Jiří Štolfa Revmatologický ústav, Praha
- 5 **Použití monoklonálních protilátek v revmatologii**  
MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN, Plzeň
- 6 **Přehled závažných lékových interakcí antibiotik**  
PharmDr. Lenka Součková Ph.D. Farmakologický ústav LF MU, Klinika dětské onkologie FN Brno, Výzkumná infrastruktura CZECRIN FN u sv. Anny v Brně
- 7 **Noxafil 300 mg koncentrát pro infuzní roztok – lékový profil**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha
- 7 **Má antiangiogenní léčba u karcinomu prsu význam?**  
MUDr. Tomáš Svoboda, Ph.D. Onkologická a radioterapeutická klinika FN, Plzeň
- 7 **Palbociclib v léčbě metastatického karcinomu prsu**  
MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno
- 8 **Imunoterapie nádorových onemocnění z pohledu imunologa**  
doc. MUDr. Eva Zavadová, CSc. | prof. MUDr. Terezie Fučíková, DrSc. | MUDr. Jan Špaček | MUDr. Michal Vočka | doc. MUDr. Bohuslav Konopásek, CSc. Onkologická klinika 1. LF UK a VFN, Praha PharmDr. Irena Netíková, Ph.D. Oddělení klinické farmakologie a farmacie VFN, Praha
- 8 **Farmakologická léčba kašle**  
MUDr. Stanislav Konštický, CSc. Lékařská fakulta Hradec Králové a Lázně Bělohrad
- 8 **Nová naděje pro pacienty s Crohnovou chorobou: ustekinumab, monoklonální protilátka anti-IL-12/23**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 8 **Fixní kombinace naltrexon/bupropion**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha
- 9 **Terapeutický potenciál fixní kombinace grazoprevir/elbasvir v léčbě hepatitidy C**  
MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

# Recidivující infekce horních cest dýchacích – podpora imunity

doc. MUDr. Jaromír Bystroň, CSc. Oddělení alergologie a klinické imunologie FN, Olomouc

- 1 Bystroň, J.: Bakteriální imunomodulátory – současné použití v klinické praxi. *Remedia*, 2010, 20, s. 298–304.
- 2 Bystroň, J.: Využití bakteriálních lysátů v praxi. *Medicina pro praxi*, 2012, 9, s. 336–341.
- 3 Cazzola, M. – Anapurapu, S. – Page, C. P.: Polyvalent mechanical bacterial lysate for the prevention of recurrent respiratory infection: a metaanalysis. *Pulm Pharmacol Ther*, 2012, 25, s. 62–68.
- 4 Heřt, J.: Alternativní medicína a léčitelství. Kritický pohled. Dostupné z: [www.sysifos.cz/files/Alternativni\\_medicina\\_Hert.pdf](http://www.sysifos.cz/files/Alternativni_medicina_Hert.pdf), vyhledáno 12. 10. 2016.
- 5 Jeseník, M. – Regnerová, Z. – Bánovčin, P., et al.: *Recidivující infekce dýchacích cest a imunomodulácia u dětí*. Mladá fronta, Praha, 2012.
- 6 Koatz, A. M. – Coe, N. A. – Ciceron, A., et al.: Clinical and immunological benefit of OM-85 bacterial lysate in patients with allergic rhinitis, asthma and COPD and recurrent respiratory infections. *Lung*, 2016, s. 1–11, doi:10.1007/s00408-016-9880-5.
- 7 Steurer-Stey, C. – Lagler, L. – Strub, D. A., et al.: Oral purified bacterial extracts in acute respiratory tract infections in childhood: a systematic quantitative review. *Eur J Pediatr*, 2007, 166, s. 365–376.

## Biologická léčba astmatu – nové cíle a perspektivy

prof. MUDr. Ilja Stríž, CSc. Pracoviště klinické a transplantační imunologie IKEM, Praha

- 1 Meyers, D. A. – Bleeker, E. R. – Holloway, J. W., et al.: Asthma genetics and personalised medicine. *Lancet Respir Med*, 2014, 2, s. 405–415.
- 2 Striz, I. – Brabcova, E. – Kolesa, L., et al.: Cytokine networking of innate immunity cells: a potential target of therapy. *Clin Science*. 2014, 126, s. 593–612.
- 3 Holgate, S. T.: Immune circuits in asthma. *Curr Opin Pharm*. 2013, 13, s. 345–350.
- 4 Zhao, P. – Xiao, X. – Ghobrial, R. M. – Li, X. C.: IL-9 and Th9 cells: progress and challenges. *Int Immunol*, 2013, 25, s. 547–551.
- 5 Eyerich, K. – Eyerich, S.: Th22 cells in allergic disease. *Allergo J Int*, 2015, 24, s. 1–7.
- 6 Chesne, J. – Braza, F. – Mahay, G., et al.: IL-17 in severe asthma. Where do we stand? *Am J Respir Critical Care Med*, 2014, 190, s. 1094–1101.
- 7 Wang, Y. H. – Liu, Y. J.: The IL-17 cytokine family and their role in allergic inflammation. *Curr Opin Immunol*, 2008, 20, s. 697–702.
- 8 Striz, I. – Mio, T. – Adachi, Y., et al.: IL-4 induces ICAM-1 expression in human bronchial epithelial cells and potentiates TNF-alpha. *Am J Physiol*, 1999, 277, s. L58–64.
- 9 Hart, T. K. – Blackburn, M. N. – Brigham-Burke, M., et al.: Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. *Clin Exp Immunol*, 2002, 130, s. 93–100.
- 10 Chaker, A. M. – Shamji, M. H. – Dumitru, F. A., et al.: Short-term subcutaneous grass pollen immunotherapy under the umbrella of anti-IL-4: A randomized controlled trial. *J Allergy Clin Immunol*, 2016, 137, s. 452–461, e9.
- 11 Corren, J. – Lemanske, R. F. – Hanania, N. A., et al.: Lebrikizumab treatment in adults with asthma. *New Eng J Med*, 2011, 365, s. 1088–1098.
- 12 Izuhara, K. – Ohta, S. – Ono, J.: Using periostin as a biomarker in the treatment of asthma. *Allergy, asthma & immunology research*, 2016, 8, s. 491–498.
- 13 Hua, F. – Dubbing, J. – Reinisch, W., et al.: A pharmacokinetic comparison of anakinzumab, an anti-IL-13 monoclonal antibody, among healthy volunteers, asthma and ulcerative colitis patients. *British J Clin Pharm*, 2015, 80, s. 101–109.
- 14 Reinisch, W. – Panes, J. – Khurana, S., et al.: Anakinzumab, an anti-interleukin 13 monoclonal antibody, in active UC: efficacy and safety from a phase IIa randomised multicentre study. *Gut*, 2015, 64, s. 894–900.
- 15 Antohe, I. – Croitoru, R. – Antoniu, S.: Tralokinumab for uncontrolled asthma. *Expert Opin Biol Ther*, 2013, 13, s. 323–326.
- 16 Brightling, C. E. – Chanez, P. – Leigh, R., et al.: Efficacy and safety of tralokinumab in patients with severe uncontrolled asthma: a randomised, double-blind, placebo-controlled, phase 2b trial. *Lancet Respir Med*, 2015, 3, s. 692–701.
- 17 De Boever, E. H. – Ashman, C. – Cahn, A. P., et al.: Efficacy and safety of an anti-IL-13 mAb in patients with severe asthma: a randomized trial. *J Allergy Clin Immunol*, 2014, 133, s. 989–996.
- 18 Rothenberg, M. E. – Wen, T. – Greenberg, A., et al.: Intravenous anti-IL-13 mAb QAX576 for the treatment of eosinophilic esophagitis. *J Allergy Clin Immunol*, 2015, 135, s. 500–507.
- 19 Wenzel, S. – Ford, L. – Pearlman, D., et al.: Dupilumab in persistent asthma with elevated eosinophil levels. *New Eng J Med*, 2013, 368, s. 2455–2466.
- 20 Thaci, D. – Simpson, E. L. – Beck, L. A., et al.: Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. *Lancet*, 2016, 387, s. 40–52.
- 21 Wenzel, S. – Wilbraham, D. – Fuller, R., et al.: Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. *Lancet*, 2007, 370, s. 1422–1431.
- 22 Stagatt, R. E. – Otulana, B. A. – Hawkins, G. A., et al.: IL-4 receptor polymorphisms predict reduction in asthma exacerbations during response to an anti-IL-4 receptor alpha antagonist. *J Allergy Clin Immunol*, 2012, 130, s. 516–522, e4.
- 23 Varricchi, G. – Bagnasco, D. – Borriello, F., et al.: Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs. Current opinion in allergy and clinical immunology. 2016, 16, s. 186–200.
- 24 Pavord, I. D. – Korn, S. – Howarth, P., et al.: Mepolizumab for severe eosinophilic asthma (DREAM) a multicentre, double-blind, placebo-controlled trial. *Lancet*, 2012, 380, s. 651–659.
- 25 Flood-Page, P. – Menzies-Gow, A. – Phipps, S., et al.: Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. *J Clin Invest*, 2003, 112, s. 1029–1036.
- 26 Lugogo, N. – Domino, C. – Chanez, P., et al.: Long-term efficacy and safety of mepolizumab in patients with severe eosinophilic asthma: a multi-center, open-label, phase IIIb study. *Clin Ther*, 2016, 38, s. 2058–2070, e1.
- 27 Astro, M. – Zangrilli, J. – Wechsler, M. E., et al.: Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. *Lancet Respir Med*, 2015, 3, s. 355–366.
- 28 Maselli, D. J. – Velez, M. I. – Rogers, L.: Reslizumab in the management of poorly controlled asthma: the data so far. *J Asthma Allergy*, 2016, 9, s. 155–162.
- 29 Kolbeck, R. – Kozhich, A. – Koike, M., et al.: MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. *J Allergy Clin Immunol*, 2010, 125, s. 1344–1353, e2.
- 30 Bleeker, E. R. – FitzGerald, J. M. – Chanez, P., et al.: Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIRIOCCO): a randomised, multicentre, placebo-controlled phase 3 trial. *Lancet*, září 2016.
- 31 FitzGerald, J. M. – Bleeker, E. R. – Nair, P., et al.: Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. *Lancet*, září 2016.
- 32 Busse, W. W. – Holgate, S. – Erwin, E., et al.: Randomized, double-blind, placebo-controlled study of brodalumab, a human anti-IL-17 receptor monoclonal antibody, in moderate to severe asthma. *Am J Respir Crit Care Med*, 2013, 188, s. 1294–1302.
- 33 Cheby, G. – Arima, M. – Honda, K., et al.: Anti-interleukin-9 antibody treatment inhibits airway inflammation and hyperreactivity in mouse asthma model. *Am J Respir Crit Care Med*, 2002, 166, s. 409–416.
- 34 Oh, C. K. – Leigh, R. – McLaurin, K. K., et al.: A randomized, controlled trial to evaluate the effect of an anti-interleukin-9 monoclonal antibody in adults with uncontrolled asthma. *Res Rep*, 2013, 14, s. 93.
- 35 Hanf, G. – Brachmann, I. – Kleine-Tebbe, J., et al.: Omalizumab decreased IgE-release and induced changes in cellular immunity in patients with allergic asthma. *Allergy*, 2006, 61, s. 1141–1144.
- 36 MacGlashan, D. Jr.: Therapeutic efficacy of omalizumab. *J Allergy Clin Immunol*, 2009, 123, s. 114–115.
- 37 Gauvreau, G. M. – Arm, J. P. – Boulet, L. P., et al.: Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. *J Allergy Clin Immunol*, 2016, 138, s. 1051–1059.
- 38 Nyborg, A. C. – Zacco, A. – Ettinger, R., et al.: Development of an antibody that neutralizes soluble IgE and eliminates IgE expressing B cells. *Cell Mol Immunol*, 2016, 13, s. 391–400.
- 39 Hartus, J. M. – Maciuga, R. – Bradley, M. S., et al.: A randomized trial of the efficacy and safety of quilizumab in adults with inadequately controlled allergic asthma. *Res Rep*, 2016, 17, s. 29.
- 40 Harris, J. M. – Cabanski, C. R. – Scheerens, H., et al.: A randomized trial of quilizumab in adults with refractory chronic spontaneous urticaria. *J Allergy Clin Immunol*, červenec 2016.
- 41 Poole, J. A. – Meng, J. – Reff, M., et al.: Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. *J Allergy Clin Immunol*, 2005, 116, s. 780–788.
- 42 Sulaiman, I. – Lim, J. C. – Soo, H. L., et al.: Molecularly targeted therapies for asthma: Current development, challenges and potential clinical translation. *Pulm Pharm Ther*, 2016, 40, s. 52–68.
- 43 Tan, H. T. – Sugita, K. – Akdis, C. A.: Novel biologicals for the treatment of allergic diseases and asthma. *Cur Allergy Asthma Reports*, 2016, 16, s. 70.

# Novinky v léčbě hypertenze

prof. MUDr. Jiří Vítovec, CSc., FESC I. interní kardiologická klinika, LF MU a FN u sv. Anny, Brno  
prof. MUDr. Jindřich Špinar, CSc., FESC Interní kardiologická klinika, LF MU a FN Brno, Brno-Bohunice

- 1 **Filipovský, J. – Widimský, J. – Ceral, J., et al.**: Diagnostické a léčebné postupy u arteriální hypertenze – verze 2012. Doporučení České společnosti pro hypertenzi. *Vnitřní Léčba*, 2012, 58, s. 785–801.
- 2 **Rosolová, H.**: Kombinovaná léčba arteriální hypertenze. *Vnitřní Léčba*, 2013, 59, s. 366–369.
- 3 **Vítovec, J. – Špinar, J. – Widimský, J.**: Fixní kombinace u hypertenze – aktuální. *Arteriální hypertenze – současné klinické trendy XIII*. Triton 2015, s. 129–133.
- 4 **Souček, M.**: Kombinovaná léčba hypertenze blokátory osy renin-angiotenzin. *Vnitřní Léčba*, 2009, 55, s. 719–723.
- 5 **Bangalore, S. – Kamalakkannan, G. – Parkar, S., et al.**: Fixed-dose combinations improve medication compliance: a meta-analysis. *Am J Med*, 2007, 120, s. 713–719.
- 6 **Vítovec, J. – Špinar, J.**: Co přináší fixní kombinace kandesartanu a amlodipinu? *Vnitřní Léčba*, 2016, 62, s. 317–321.
- 7 **Sliva, J.**: Concor Combi (amlodipin + bisoprolol): nová fixní kombinace v léčbě hypertenze. *První linie*, 2012, 2, s. 10–12.
- 8 **Brugts, J. – Bertrand, M. – Remme, W., et al.**: The treatment benefit of the ACE inhibitor on top of beta-blocker therapy in patients with vascular disease. *J Hypertens*, 2016, 34, s. PP13.04.
- 9 **Widimský, J. Jr.**: První fixní kombinace: perindopril arginin-indapamid-amlodipin. *Vnitřní Léčba*, 2014, 60, s. 801–807.
- 10 **Špinar, J. – Vítovec, J. – Bendová, M.**: Kombinovaná léčba u obtížně kontrolované hypertenze. *Arteriální hypertenze – současné klinické trendy XIII*. Triton, 2015, s. 135–148.
- 11 **Kociánová, E.**: Fixní trojkombinace perindopril arginin/indapamid/amlodipin v léčbě arteriální hypertenze. *Remedia*, 2014, 24, s. 516–519.
- 12 **Vítovec, J. – Špinar, J.**: Fixní kombinace v klinické praxi. *KARIM*, 2016, 18, s. 84.
- 13 **Špinar, J. – Vítovec, J. – Špinarová, L.**: Fixní kombinací léčba hypertenze. *KARIM*, 2016, 18, s. 85–93.
- 14 **Špinar, J. – Vítovec, J.**: Studie EUROPA a ASCOT znovu přepisují léčbu. *Hypertenze a KV prevence*, 2016, 5, s. 13–17.
- 15 **Rosolová, H.**: Význam fixní kombinace atorvastatin, perindopril a amlodipin (Lipertence). *Farmakoterapie*, 2016, 12, s. 484–489.
- 16 **Widimský, J. Jr.**: Lipertence® – první fixní trojkombinace atorvastatinu, perindopril argininu a amlodipinu. *Hypertenze a KV prevence*, 2016, 5, s. 63–67.
- 17 **Špinar, J. – Vítovec, J.**: Lipertence – dva problémy, jedno řešení. *KARIM*, 2016, 18, v tisku.
- 18 **Bertrand, M. E. – Vlachopoulos, C. – Mourad, J. J.**: Triple combination therapy for global cardiovascular risk: atorvastatin, perindopril, and amlodipine. *Am J Cardiovasc Drugs*, 2016, 16, s. 241–253.

# Metabolický syndrom v roce 2016

prof. MUDr. Milan Kvapil, CSc., MBA Interní klinika FN Motol a 2. LF UK, Praha

- 1 **Reaven, G. M.**: Syndrome X. *Blood Press Suppl*, 1992, 4, s. 13–16.
- 2 **Reaven, G. M.**: Role of insulin resistance in human disease (syndrome X): an expanded definition. *Annu Rev Med*, 1993, 44, s. 121–131.
- 3 **Reaven, G. M.**: Syndrome X: 6 years later. *J Intern Med Suppl*, 1994, 736, s. 13–22.
- 4 **Miranda, P. J. – DeFronzo, R. A. – Califf, R. M., et al.**: Metabolic syndrome: evaluation of pathological and therapeutic outcomes. *Am Heart J*, 2005, 149, s. 20–32.
- 5 **DeFronzo, R. A.**: Lilly lecture 1987. The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDM. *Diabetes*, 1988, 37, s. 667–687.
- 6 **DeFronzo, R. A. – Bonadonna, R. C. – Ferrannini, E.**: Pathogenesis of NIDDM. A balanced overview. *Diabetes Care*, 1992, 15, s. 318–368.
- 7 **DeFronzo, R. A. – Ferrannini, E.**: Insulin resistance. A multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease. *Diabetes Care*, 1991, 14, s. 173–194.
- 8 **Alberti, K. G. – Eckel, R. H. – Grundy, S. M., et al.**: International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; International Association for the Study of Obesity. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. *Circulation*, 2009, 120, s. 1640–1645.
- 9 **Wang, C. C. – Goalstone, M. L. – Draznin, B.**: Molecular mechanisms of insulin resistance that impact cardiovascular biology. *Diabetes*, 2004, 53, s. 2735–2740.
- 10 **Reilly, M. P. – Rader, D. J.**: The metabolic syndrome: more than the sum of its parts? *Circulation*, 2003, 108, s. 1546–1551.
- 11 **Kreier, F. – Yilmaz, A. – Kalsbeek, A., et al.**: Hypothesis: shifting the equilibrium from activity to food leads to autonomic imbalance and the metabolic syndrome. *Diabetes*, 2003, 52, s. 2652–2656.
- 12 **Grundy, S. M.**: Pre-diabetes, metabolic syndrome, and cardiovascular risk. *J Am Coll Cardiol*, 2012, 59, s. 635–643.
- 13 **Mottilo, S. – Filion, K. B. – Genest, J., et al.**: The metabolic syndrome and cardiovascular risk: a systematic review and meta-analysis. *J Am Coll Cardiol*, 2010, 56, s. 1113–1132.
- 14 **Haffner, S. M. – Stern, M. P. – Hazuka, H. P., et al.**: Cardiovascular risk factors in confirmed prediabetic individuals. Does the clock for coronary heart disease start ticking before the onset of clinical diabetes? *JAMA*, 1990, 263, s. 2893–2898.
- 15 **Stratton, I. M. – Adler, A. L. – Neil, H. A., et al.**: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. *BMJ*, 2000, 321, s. 405–412.
- 16 **Grundy, S. M. – Cleeman, J. I. – Daniels, S. R., et al.**: American Heart Association; National Heart, Lung, and Blood Institute. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. *Circulation*, 2005, 112, s. 2735–2752.
- 17 **Geurin, M. D. – St Anna, L.**: Thiazolidinedione therapy for managing metabolic syndrome. *Am Fam Physician*, 2010, 82, s. 1553–1554.
- 18 **Gerber, P. – Lübbers, G. – Heuser, S., et al.**: Effects of pioglitazone on metabolite control and blood pressure: a randomised study in patients with type 2 diabetes mellitus. *Curr Med Res Opin*, 2003, 19, s. 532–539.
- 19 **Normandy, J. A. – Charbonnel, B. – Eckland, D. J., et al.**: PROactive Investigators. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitazone Clinical Trial In macroVascular Events): a randomised controlled trial. *Lancet*, 2005, 366, s. 1279–1289.
- 20 **Erdmann, E. – Normandy, J. A. – Charbonnel, B., et al.**: PROactive Investigators. The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. *J Am Coll Cardiol*, 2007, 49, s. 1772–1780.
- 21 **Wilcox, R. – Bousser, M. G. – Betteridge, D. J., et al.**: PROactive Investigators. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitazone Clinical Trial In macroVascular Events 04). *Stroke*, 2007, 38, s. 865–873.
- 22 **Sperling, L. S. – Mechanick, J. I. – Neeland, I. J., et al.**: The Cardio-Metabolic Health Alliance: Working toward a new care model for the metabolic syndrome. *J Am Coll Cardiol*, 2015, 66, s. 1050–1067.
- 23 **Brož, J. – Honěk, P. – Dušek, L., et al.**: The mortality of patients with diabetes mellitus using oral antidiabetic drugs in the Czech Republic decreased over the decade of 2003–2013 and came closer to the population average. *Vnitřní Léčba*, 2015, 61, s. S14–S20.

# Klinická farmakologie přímých perorálních antikoagulantů

doc. MUDr. Karel Urbánek, Ph.D. Ústav farmakologie LF UP a FN, Olomouc

- 1 **Wardrop, D. – Keeling, D.**: The story of the discovery of heparin and warfarin. *Br J Haematol*, 2008, 141, s. 757–763.
- 2 **SPC Pradaxa**, dostupné z: [www.sukl.cz](http://www.sukl.cz)
- 3 **Stangier, J. – Rathgen, K. – Stähle, H., et al.**: The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects. *Br J Clin Pharmacol*, 2007, 64, s. 292–303.
- 4 **Stangier, J. – Ericsson, B. – Dahl, O. E., et al.**: Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. *J Clin Pharmacol*, 2005, 45, s. 555–563.
- 5 **Khadzhynov, D. – Wagner, F. – Formela, S.**: Effective elimination of dabigatran by haemodialysis. A phase I single-centre study in patients with end-stage renal disease. *Thromb Haemost*, 2013, 109, s. 596–605.
- 6 **Stangier, J. – Clemens, A.**: Pharmacology, pharmacokinetics, and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor. *Clin Appl Thromb Hemost*, 2009, 15, s. 95–165.
- 7 **Stangier, J. – Stähle, H. – Rathgen, K., et al.**: Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. *Clin Pharmacokinet*, 2008, 47, s. 47–59.
- 8 **Reilly, P. A. – Lehr, T. – Haertter, S., et al.**: The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients. The RE-LY Trial. *J Am Coll Cardiol*, 2014, 63, s. 321–328.
- 9 **Chan, K. E. – Edelman, E. R. – Wenger, J. B., et al.**: Dabigatran and rivaroxaban use in atrial fibrillation patients on hemodialysis. *Circulation*, 2015, 131, s. 972–979.
- 10 **Stangier, J. – Stähle, H. – Rathgen, K., et al.**: Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment. *J Clin Pharmacol*, 2008, 48, s. 1411–1419.
- 11 **Dans, A. L. – Connolly, S. J. – Wallentin, L., et al.**: Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long-term anticoagulation therapy (RE-LY) trial. *Circulation*, 2013, 127, s. 634–640.
- 12 **Dabigatran Briefing Document**. 27. 8. 2010, dostupné z: <http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf>, vyhledáno 17. 10. 2016.
- 13 **Härterter, S. – Sennewald, R. – Nehmiz, G., et al.**: Oral bioavailability of dabigatran etexilate (Pradaxa) after co-medication with verapamil in healthy subjects. *Br J Clin Pharmacol*, 2013, 75, s. 1053–1062.
- 14 **Härterter, S. – Koenen-Bergmann, M. – Sharma, A., et al.**: Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin. *Br J Clin Pharmacol*, 2012, 74, s. 490–500.
- 15 **Urbánek, K.**: Přímá perorální antikoagulantia – perspektivy terapeutického monitorování. *Kardiol Rev Int Med*, 2015, 17, s. 76–81.
- 16 **Connolly, S. J. – Ezekowitz, M. D. – Yusuf, S., et al.**: Dabigatran versus warfarin in patients with atrial fibrillation. The RE-LY investigators. *N Engl J Med*, 2009, 361, s. 1139–1151.
- 17 **Southworth, M. R. – Teichman, M. E. – Unger, E. F.**: Dabigatran

- and postmarketing reports of bleeding. *N Engl J Med*, 2013, 368, s. 1272–1274.
- 18 **Douwifis, J. – Buckinx, F. – Mullier, F., et al.**: Dabigatran etexilate and risk of myocardial infarction, other cardiovascular events, major bleeding, and all-cause mortality: a systematic review and metaanalysis of randomized controlled trials. *J Am Heart Assoc*, 2014, 3, s. e000515.
  - 19 **Lin, L. – Lim, W. S. – Zhou, H. J., et al.**: Clinical and safety outcomes of oral antithrombotics for stroke prevention in atrial fibrillation: a systematic review and network metaanalysis. *J Am Med Dir Assoc*, 2015, 16, s. 1103.e1–1103.e19.
  - 20 **Kubitza, D. – Becka, M. – Voith, B., et al.**: Safety, pharmacodynamics, and pharmacokinetics of single doses of BAY 59-7939, an oral direct factor Xa inhibitor. *Clin Pharmacol Ther*, 2005, 78, s. 412–421.
  - 21 **Kubitza, D. – Becka, M. – Wensing, G., et al.**: Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 – an oral, direct Factor Xa inhibitor – after multiple dosing in healthy male subjects. *Eur J Clin Pharmacol*, 2005, 61, s. 873–880.
  - 22 **Moore, K. T. – Krook, M. A. – Vaidyanathan, S., et al.**: Rivaroxaban crushed tablet suspension characteristics and relative bioavailability in healthy adults when administered orally or via nasogastric tube. *Clin Pharmacol Drug Dev*, 2014, 3, s. 321–327.
  - 23 **Stampfuss, J. – Kubitza, D. – Becka, M., et al.**: The effect of food on the absorption and pharmacokinetics of rivaroxaban. *Int J Clin Pharmacol Ther*, 2013, 51, s. 549–561.
  - 24 **Kubitza, D. – Becka, M. – Roth, A., et al.**: Dose-escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects. *Curr Med Res Opin*, 2008, 24, s. 2757–2765.
  - 25 **Lehmann, T. – Hober, K. E. – Baumann, M., et al.**: Massive human rivaroxaban overdose. *Thromb Haemost*, 2014, 112, s. 834–836.
  - 26 **Mueck, W. – Becka, M. – Kubitza, D., et al.**: Population model of the pharmacokinetics and pharmacodynamics of rivaroxaban – an oral, direct factor Xa inhibitor – in healthy subjects. *Int J Clin Pharmacol Ther*, 2007, 45, s. 335–344.
  - 27 SPC Xarelto, dostupné z: [www.sukl.cz](http://www.sukl.cz)
  - 28 European Medicines agency: CHMP assessment report for Xarelto; 2008, dostupné z: [http://www.ema.europa.eu/docs/en\\_GB/document\\_library/EPAR\\_-\\_Public\\_assessment\\_report/human/000944/WCS00057122.pdf](http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/000944/WCS00057122.pdf), vyhledáno 27. 12. 2015.
  - 29 **Weinz, C. – Schwarz, T. – Kubitza, D., et al.**: Metabolism and excretion of rivaroxaban, an oral, direct Factor Xa inhibitor, in rats, dogs and humans. *Drug Metab Dispos*, 2009, 37, s. 1056–1064.
  - 30 **Mueck, W. – Kubitza, D. – Becka, M.**: Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. *Br J Clin Pharmacol*, 2013, 79, s. 455–466.
  - 31 **Kubitza, D. – Becka, M. – Zuehlsdorf, M., et al.**: Body weight has limited influence on the safety, tolerability, pharmacokinetics, or pharmacodynamics of rivaroxaban (BAY 59-7939) in healthy subjects. *J Clin Pharmacol*, 2007, 47, s. 2018–2226.
  - 32 **Piccini, J. P. – Hellkamp, A. S. – Washam, J. B., et al.**: Polypharmacy and the efficacy and safety of rivaroxaban versus warfarin in the prevention of stroke in patients with nonvalvular atrial fibrillation. *Circulation*, 2016, 133, s. 352–360.
  - 33 **Kubitza, D. – Becka, M. – Zuehlsdorf, M., et al.**: Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. *J Clin Pharmacol*, 2006, 46, s. 549–558.
  - 34 **Moore, K. T. – Plotnikov, A. N. – Thyssen, A., et al.**: Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. *J Cardiovasc Pharmacol*, 2011, 58, s. 581–588.
  - 35 **Moore, K. T. – Vaidyanathan, S. – Natarajan, J., et al.**: An open-label study to estimate the effect of steady-state erythromycin on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban in subjects with renal impairment and normal renal function. *J Clin Pharmacol*, 2014, 54, s. 1407–1420.
  - 36 **Wannhoff, A. – Weiss, K. H. – Stremmel, W., et al.**: Increased levels of rivaroxaban in patients after liver transplantation treated with cyclosporine A. *Transplantation*, 2014, 98, s. e12–13.
  - 37 **Camm, A. J. – Amarencu, P. – Haas, S., et al.**: XANTUS: a real-world, prospective, observational study of patients treated with rivaroxaban for stroke prevention in atrial fibrillation. *Eur Heart J*, 2016, 37, s. 1145–1153.
  - 38 **Patel, M. R. – Mahaffey, K. W. – Garg, J., et al.**: Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. ROCKET AF Investigators. *N Engl J Med*, 2011, 365, s. 883–891.
  - 39 **Watkins, P. B. – Desai, M. – Berkowitz, S. D., et al.**: Evaluation of drug induced serious hepatotoxicity (eDISH): application of this data organization approach to phase III clinical trials of rivaroxaban after total hip or knee replacement surgery. *Drug Saf*, 2011, 34, s. 243–252.
  - 40 **Barrett, P. – Vuppalaanchi, R. – Masuoka, H., et al.**: Severe drug-induced skin and liver injury from rivaroxaban. *Dig Dis Sci*, 2015, 60, s. 1856–1858.
  - 41 **Liakoni, E. – Rätz Bravo, A. E. – Terracciano, L., et al.**: Symptomatic hepatocellular liver injury with hyperbilirubinemia in two patients treated with rivaroxaban. *JAMA Intern Med*, 2014, 174, s. 1683–1686.
  - 42 **Lambert, A. – Cordeanu, M. – Gaertner, S., et al.**: Rivaroxaban-induced liver injury: Results from a venous thromboembolism registry. *Int J Cardiol*, 2015, 191, s. 265–266.
  - 43 **Raschi, E. – Poluzzi, E. – Koci, A., et al.**: Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration adverse event reporting system. *Br J Clin Pharmacol*, 2015, 80, s. 285–293.
  - 44 **Raghavan, N. – Frost, Ch. – Yu, Z., et al.**: Apixaban. Metabolism and pharmacokinetics after oral administration to humans. *Drug Metab Dispos*, 2009, 37, s. 74–81.
  - 45 **Frost, Ch. – Wang, J. – Nepal, S., et al.**: Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. *Br J Clin Pharmacol*, 2013, 75, s. 476–487.
  - 46 **Frost, C. – Nepal, S. – Wang, J., et al.**: Safety, pharmacokinetics and pharmacodynamics of multiple oral doses of apixaban, a factor Xa inhibitor, in healthy subjects. *Br J Clin Pharmacol*, 2013, 76, s. 776–786.
  - 47 SPC Eliquis, dostupné z: [www.sukl.cz](http://www.sukl.cz)
  - 48 **Song, Y. – Wang, X. – Perlstain, I., et al.**: Relative bioavailability of apixaban solution or crushed tablet formulations administered by mouth or nasogastric tube in healthy subjects. *Clin Ther*, 2015, 37, s. 1703–1712.
  - 49 **He, K. – Luettgen, J. M. – Zhang, D., et al.**: preclinical pharmacokinetics and pharmacodynamics of apixaban, a potent and selective factor Xa inhibitor. *Eur J Drug Metab Pharmacokinet*, 2011, 36, s. 129–139.
  - 50 **Lam, W. – Reyes, M. – Seger, J.**: Plasma exchange for urgent apixaban reversal in a case of hemorrhagic tamponade after pacemaker implantation. *Tex Heart Inst J*, 2015, 42, s. 377–380.
  - 51 **Franchini, M. – Lippi, G.**: Prothrombin complex concentrates: an update. *Blood Transfus*, 2010, 8, s. 149–154.
  - 52 **Wang, L. – Zhang, D. – Raghavan, N., et al.**: In vitro assessment of metabolic drug-drug interaction potential of apixaban through cytochrome P450 phenotyping, inhibition, and induction studies. *Drug Metab Dispos*, 2010, 38, s. 448–458.
  - 53 **Chang, M. – Yu, Z. – Shenker, A., et al.**: Effect of renal impairment on the pharmacokinetics, pharmacodynamics, and safety of apixaban. *J Clin Pharmacol*, 2015, doi: 10.1002/jcph.633.
  - 54 **Frost, C. – Wang, J. – Li, C., et al.**: Single-dose safety and pharmacokinetics of apixaban in subjects with mild or moderate hepatic impairment. *Clin Pharmacol Ther*, 2009, 85, s. S34 (P1-84).
  - 55 **Alexander, J. H. – Lopes, R. D. – Thomas, L., et al.**: Apixaban vs. warfarin with concomitant aspirin in patients with atrial fibrillation: insights from ARISTOTLE trial. *Eur Heart J*, 2014, 35, s. 224–232.
  - 56 **Frost, C. – Shenker, A. – Sandhi, M. D., et al.**: Evaluation of the effect of naproxen on the pharmacokinetics and pharmacodynamics of apixaban. *Br J Clin Pharmacol*, 2014, 78, s. 877–885.
  - 57 **Upreti, V. V. – Song, Y. – Wang, J., et al.**: Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. *Clin Pharmacol*, 2013, 5, s. 59–66.
  - 58 **Wang, X. – Mondal, S. – Wang, J., et al.**: Effect of activated charcoal on apixaban pharmacokinetics in healthy subjects. *Am J Cardiovasc Drugs*, 2014, 14, s. 147–154.
  - 59 **Frost, C. E. – Byon, W. – Song, Y., et al.**: Effect of ketoconazole and diltiazem on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor. *Br J Clin Pharmacol*, 2015, 79, s. 838–846.
  - 60 **Granger, C. B. – Alexander, J. H. – McMurray, J. J. V., et al.**: ARISTOTLE Investigators: Apixaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2011, 365, s. 981–992.
  - 61 **Agnelli, G. – Bulle, H. R. – Cohen, A., et al.**: AMPLIFY investigators. Oral apixaban for the treatment of acute venous thromboembolism. *N Engl J Med*, 2013, 369, s. 799–808.
  - 62 **Agnelli, G. – Bulle, H. R. – Cohen, A., et al.**: Apixaban for extended treatment of venous thromboembolism. *N Engl J Med*, 2013, 368, s. 699–708.

## Edoxaban – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 **Zafar, M. U. – Vorchheimer, D. A. – Gaztanaga, J., et al.**: Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber. *Thromb Haemost*, 2007, 98, s. 883–888.
- 2 **Zahir, H. – Matsushima, N. – Halim, A. B., et al.**: Edoxaban administration following enoxaparin: a pharmacodynamic, pharmacokinetic, and tolerability assessment in human subjects. *Thromb Haemost*, 2012, 108, s. 166–175.
- 3 **Bounameaux, H. – Camm, A. J.**: Edoxaban: an update on the new oral direct factor Xa inhibitor. *Drugs*, 2014, 74, s. 1209–1231.
- 4 **Giugliano, R. P. – Ruff, C. T. – Braunwald, E., et al.**: Edoxaban versus warfarin in patients with atrial fibrillation. *N Engl J Med*, 2013, 369, s. 2093–2104.
- 5 **Goette, A. – Merino, J. L. – Ezekowitz, M. D., et al.**: Edoxaban versus enoxaparin-warfarin in patients undergoing cardioversion of atrial fibrillation (ENSURE-AF): a randomised, open-label, phase 3b trial. *Lancet*, 2016, 388, s. 1995–2003.
- 6 **Bulle, H. R. – Decousus, H. – Grosso, M. A., et al.**: Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. *N Engl J Med*, 2013, 369, s. 1406–1415.
- 7 **Raskob, G. – Ageno, W. – Cohen, A. T., et al.**: Extended duration of anticoagulation with edoxaban in patients with venous thromboembolism: a post-hoc analysis of the Hokusai-VTE study. *Lancet Haematol*, 2016, 3, s. e228–e236.
- 8 **Raskob, G. E. – van S, N. – Segers, A., et al.**: Edoxaban for venous thromboembolism in patients with cancer: results from a non-inferiority subgroup analysis of the Hokusai-VTE randomised, double-blind, double-dummy trial. *Lancet Haematol*, 2016, 3, s. e379–e387.
- 9 **Preblich, R. – Kong, W. J. – White, R. H., et al.**: Cost-effectiveness of edoxaban for the treatment of venous thromboembolism based on the Hokusai-VTE study. *Hosp Pract*, 2015, 43, s. 249–257.

## Inovativní přístupy v léčbě roztroušené sklerózy

MUDr. Marek Peterka Neurologická klinika, LF UK a FN, Plzeň

- 1 **Oksenberg, J. R. – Baranzini, S. E. – Hauser, S. L.**: Biological concepts of multiple sclerosis pathogenesis and relationship to treatment. In: Cohen, J. A. – Rudick, R. A. (eds.): *Multiple Sclerosis Therapeutics*. Londýn, Informa Healthcare, 2007, s. 23–44.
- 2 **Kappos, L. – Lindberg, R. L. P.**: Interferons in relapsing-remitting multiple sclerosis. In: Cohen, J. A. – Rudick, R. A. (eds.): *Multiple Sclerosis Therapeutics*. Londýn, Informa Healthcare, 2007, s. 373–392.
- 3 **Kappos, L. – Freedman, M. S. – Polman, C. H., et al.**: Long term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFT trial. *Lancet Neurol*, 2009, 8, s. 987–997.
- 4 **Havrdova, E. – Galetta, S. – Hutchinson, M., et al.**: Effect of natalizumab on clinical and radiological disease activity in multiple sclerosis: a retrospective analysis of the Natalizumab Safety and Efficacy in Relapsing-Remitting Multiple Sclerosis (AFFIRM) study. *Lancet Neurol*, 2009, 8, s. 254–260.
- 5 **Kappos, L. – Bates, D. – Edan, G., et al.**: Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring. *Lancet Neurol*, 2011, 10, s. 745–758.
- 6 Biogen. Biogen Idex Medical information, dostupné z: <https://medinfo.biogenidec.com/>, vyhledáno 31. 8. 2016.
- 7 **Chun, J. – Hartung, H. P.**: Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. *Clin Neuropharmacol*, 2010, 33, s. 91–101.

- 8 Cohen, J. A. – Barkhof, F. – Comi, G., et al.: TRANSFORMS Study Group. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 402–415.
- 9 Kappos, L. – Radue, E. W. – O'Connor, P., et al.: FREEDOMS Study Group. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. *N Engl J Med*, 2010, 362, s. 387–401.
- 10 New recommendations to minimise risks of the rare brain infection PML and a type of skin cancer with Gilenya. Doporučení EMA, 18. 12. 2015).
- 11 Claussen, M. C. – Kom, T.: Immune mechanisms of new therapeutic strategies in MS – Teriflunomide. *Clinical Immunology*, 2012, 142, s. 49–56.
- 12 Gold, R. – Dolinsky, J. S.: Patophysiology of multiple sclerosis and the place of teriflunomide. *Acta Neurol Scand*, 2011, 124, s. 75–84.
- 13 O'Connor, P. – Wolinsky, J. S. – Confavreux, Ch., et al.: Randomized trial of oral teriflunomide for relapsing multiple sclerosis. *N Engl J Med*, 2011, 365, s. 1293–1303.
- 14 Kappos, L. – Comi, G. – Confavreux, C., et al.: The efficacy and safety of teriflunomide in patients with relapsing MS: results from TOWER, a phase III, placebo controlled study. Prezentováno na: Congress of the European Committee for Treatment and Research in Multiple Sclerosis 2012, abstrakt 153. *Mult Scler J*, 2012, 18, s. 50–51.
- 15 Confavreux, Ch. – O'Connor, P. – Comi, G., et al.: Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double blind, placebo controlled, phase 3 trial. *Lancet Neurol*, 2014, 13, s. 247–256.
- 16 Miller, A. E. – Wolinsky, J. S. – Kappos, L., et al.: TOPIC main outcomes: efficacy and safety of once-daily oral teriflunomide in patients with clinically isolated syndrome. Prezentováno na: 29 Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS), 2.–5. 10. 2013, Kodaň.
- 17 Vermersch, P. – Czlonkowska, A. – Grimaldi, L. M., et al.: Teriflunomide versus subcutaneous interferon Beta 1a in patients with relapsing multiple sclerosis: a randomised, controlled phase 3 trial. *Mult Scler*, 2014, 20, s. 705–716.
- 18 Freedmann, M. S. – Dolinsky, J. S. – Frangin, G. A., et al.: Oral teriflunomide or placebo to addend to glatiramer acetate for 6 months in patients with relapsing multiple sclerosis: safety and efficacy results. Prezentováno na: Annual Meeting of the American Academy of neurology (AAN), 14. 4. 2010, Toronto.
- 19 Schweckendiek, W.: Behandlung von psoriasis mit lipoidlöslichen fumarsäureverbindungen. *Medizin Heute*, 1966, 15, s. 219–220.
- 20 Punker, R. A. – Gold, R.: Dimethyl fumarate for treatment of multiple sclerosis: Mechanism of action, effectiveness, and side effects. *Curr Neurol Neurosci Rep*, 2013, 13, s. 394–406.
- 21 Linker, R. A. – Lee, D. H. – Ryan, S., et al.: Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway. *Brain*, 2011, 134, s. 678–692.
- 22 Gold, R. – Kappos, L. – Arnold, D. et al.: Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. *N Engl J Med*, 2012, 367, s. 1098–1107.
- 23 Fox, R. J. – Miller, D. H. – Phillips, J. T., et al.: Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. *N Engl J Med*, 2012, 367, s. 1087–1097.
- 24 SPC Lemtrada. Dostupné z: [http://www.ema.europa.eu/docs/cs\\_CZ/document\\_library/EPAR\\_-\\_Product\\_Information/human/003718/WC500150521.pdf](http://www.ema.europa.eu/docs/cs_CZ/document_library/EPAR_-_Product_Information/human/003718/WC500150521.pdf), vyhledáno 20. 10. 2016.
- 25 Bielekova, B. – Becker, B. L.: Monoclonal antibodies in MS: mechanisms of action. *Neurology*, 2010, 74, s. S31–S40.
- 26 Coles, A. J. – Fox, E. – Vlado, A., et al.: Alemtuzumab versus interferon  $\beta$ -1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. *Lancet Neurol*, 2011, 10, s. 338–348.
- 27 Cohen, J. A. – Coles, A. J. – Arnold, D. L., et al., CARE-MS I investigators: Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing remitting multiple sclerosis: a randomised controlled phase 3 trial. *Lancet Neurol*, 2012, 380, s. 1819–1828.
- 28 Coles, A. J. – Twyman, C. L. – Arnold, D. L., et al., CARE-MS II investigators: Alemtuzumab for patient with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. *Lancet Neurol*, 2012, 380, s. 1829–1839.

## Léčba psoriatické artritidy – nové pohledy

MUDr. Jiří Štolfa Revmatologický ústav, Praha

- 1 Wright, V. – Moll, J. M.: Psoriatic arthritis. *Bull Rheum Dis*, 1971, 21, s. 627–632.
- 2 Taylor, W. – Gladman, D. – Helliwell, P., et al.: Classification criteria for psoriatic arthritis: development of new criteria from a large international study. *Arthritis Rheum*, 2006, 54, s. 2665–2673.
- 3 Kingsley, G. – Kowalczyk, A. – Taylor, H., et al.: Methotrexate is not disease modifying in psoriatic arthritis: The MIPA trial. *Arthritis Rheum*, 2010, 62, s. S277.
- 4 Ramiro, S. – Smolen, J. S. – Landewé, R., et al.: Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*, 2015, 0, s. 1–9.
- 5 Diates, L. C.: Treating to target in psoriatic arthritis. *Curr Opin Rheumatol*, 2015, 27, s. 107–110.
- 6 3<sup>rd</sup> World Congress of Psoriasis and Psoriatic Arthritis 2012, Stockholm.
- 7 Kaltwasser, J. P. – Nash, P. – Gladman, D. D., et al.: Treatment of Psoriatic Arthritis Study Group. Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis: a multinational, double-blind, randomized, placebo-controlled clinical trial. *Arthritis Rheum*, 2004, 50, s. 1939–1950.
- 8 Gusta, A. K. – Grober, J. S. – Hamilton, T. A., et al.: Sulfasalazine therapy for psoriatic arthritis: a double blind, placebo controlled trial. *J Rheumatol*, 1995, 22, s. 894–898.
- 9 Dougados, M. – van der Linden, S. – Leirisalo-Repo, M., et al.: Sulfasalazine in the treatment of spondylarthropathy. A randomized, multicentre, double blind, placebo-controlled study. *Arthritis Rheum*, 1995, 38, s. 618–627.
- 10 Clegg, D. O. – Reda, D. J. – Mejias, J., et al.: Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A department of Veterans Affairs. *Arthritis Rheum*, 1996, 39, s. 2013–2020.
- 11 Ash, Z. – Gaujoux-Viala, C. – Gossec, L., et al.: A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*, 2012, 71, s. 319–326.
- 12 Mumtaz, A. – Gallagher, P. – Kirby, B., et al.: Development of a preliminary composite disease activity index in psoriatic arthritis. *Ann Rheum Dis*, 2011, 70, s. 272–277.
- 13 Ritchlin, C. T. – Gottlieb, A. B. – McInnes, I. B., et al.: Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: results of a phase 3, multicenter, double-blind, placebo-controlled study [abstrakt 2557]. *Arthritis Rheum*, 2012, 64, s. S1080–S1081.
- 14 Ritchlin, C. – Rahman, P. – Kavanaugh, A., et al.: PSUMMIT 2 Study Group. Efficacy and safety of the anti-IL-12/23 p40 monoclonal antibody, ustekinumab, in patients with active psoriatic arthritis despite conventional non-biological and biological anti-tumour necrosis factor therapy: 6-month and 1-year results of the phase 3, multicenter, double-blind, placebo-controlled, randomised PSUMMIT 2 trial. *Ann Rheum Dis*, 2014, 73, s. 990–999.
- 15 Ramiro, S. – Smolen, J. S. – Landewé, R., et al.: Pharmacological treatment of psoriatic arthritis: a systematic literature review for the 2015 update of the EULAR recommendations for the management of psoriatic arthritis. *Ann Rheum Dis*, 2015, 0, s. 1–9.
- 16 Noordenbos, T. – Yerenko, N. – Gofta, I., et al.: Interleukin-17-positive mast cells contribute to synovial inflammation in spondylarthritides. *Arthritis Rheum*, 2012, 64, s. 99–109.
- 17 Kavanaugh, A. – McInnes, I. B. – Mease, P. J., et al.: Secukinumab provides sustained improvements in the signs and symptoms of active psoriatic arthritis in anti-TNF-naïve patients and those previously exposed to anti-TNF therapy: 52-week results from a randomized, double-blind, placebo-controlled phase 3 trial with subcutaneous dosing. ACR/ARHP Annual Meeting, publikováno 29. 9. 2015.
- 18 Schafer, P. H. – Parton, A. – Sandhi, A. K., et al.: Apremilast, a cAMP phosphodiesterase-4 inhibitor, demonstrates anti-inflammatory activity in vitro and in a model of psoriasis. *Br J Pharmacol*, 2010, 159, s. 842–855.
- 19 Schett, G. – Wollenhaupt, J. – Papp, K., et al.: Oral apremilast in the treatment of active psoriatic arthritis: results of a multicenter, randomized, double-blind, placebo-controlled study. *Arthritis Rheum*, 2012, 64, s. 3156–3167.
- 20 Kavanaugh, A. – Mease, P. J. – Gomez-Reino, J. J., et al.: Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis: results of a phase 3, randomized, controlled trial [abstract L13]. *Arthritis Rheum*, 2012, 64, s. 4172–4173.
- 21 Celgene International Sarl. Apremilast achieves statistical significance for the primary endpoint of the first phase III study (PALACE-1) in patients with psoriatic arthritis. Tisková zpráva, 2012.
- 22 Fleischman, R. – Kremer, J. – Cush, J., et al.: Placebo-controlled trial of tofacitinib monotherapy in rheumatoid arthritis. *N Engl J Med*, 2012, 367, s. 495–507.
- 23 Ghoreschi, K. – Laurinca, A. – O'Shia, J. J.: Janus kinases in immune cell signaling. *Immunol Rev*, 2009, 228, s. 273–287.
- 24 Papp, K. A. – Menter, A. – Strober, B., et al.: Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, in the treatment of psoriasis: a phase 2b randomized placebo-controlled doseranging study. *Br J Dermatol*, 2012, 167, s. 668–677.
- 25 Coates, L. C. – Kavanaugh, A. – Philip, J., et al.: Group for research and assessment of psoriasis and psoriatic arthritis 2015. Treatment recommendations for psoriatic arthritis. *Arthritis Rheumatol*, 2016, 68, s. 1060–1071.

## Použití monoklonálních protilátek v revmatologii

MUDr. David Suchý, Ph.D. Oddělení klinické farmakologie FN, Plzeň

- 1 Fusek, M. – Vitek, L. – Blahoš, J., et al.: *Biologická léčiva. Teoretické základy a klinická praxe*. Grada Publishing, Praha, 2012.
- 2 Fusek, M. – Vitek, L. – Blahoš, J., et al.: *Biologická léčiva: teoretické základy a klinická praxe*. Praha, Grada, 2012.
- 3 Pavelková, A.: *Revmatoidní artritida a biologická léčba*. Maxdorf, Praha, 2009.
- 4 Pavelka, K. – Vencovský, J.: Doporučení České revmatologické společnosti pro léčbu revmatoidní artritidy. *Česká Revmatologie*, 2010, 4, s. 182–191.
- 5 Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu ankylozující spondylitidy. *Česká Revmatologie*, 2012, 1, s. 4–12.
- 6 Štolfa, J. – Vencovský, J. – Pavelka, K.: Doporučení České revmatologické společnosti pro léčbu psoriatické artritidy. *Česká Revmatologie*, 2012, 1, s. 13–18.
- 7 Pavelka, K.: Biologická léčba revmatických onemocnění. *Acta medica*, 2013, 1, s. 24–32.
- 8 Maini, R. – St Clair, E. W. – Breedveld, F., et al.: Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group. *Lancet*, 1999, 354, s. 1932–1939.
- 9 St Clair, E. W. – van der Heijde, D. M. – Smolen, J. S., et al.: Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. *Arthritis Rheum*, 2004, 50, s. 3432–3443.
- 10 Goekoop-Ruiterman, Y. P. – Vries Boustra, J. K., et al.: Clinical and radiographic outcomes of four different treatment strategies in patients with early RA (the BEST study): A randomized controlled trial. *Arthritis Rheum*, 2005, 52, s. 3381–3390.
- 11 van der Heijde, D. – Dijkmans, B. – Geusens, P., et al.: Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). *Arthritis Rheum*, 2005, 52, s. 582–591.
- 12 Antoni, C. E. – Kavanaugh, A. – Kirkham, B., et al.: Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT). *Arthritis Rheum*, 2005, 52, s. 1227–1236.
- 13 Weinblatt, M. E. – Keystone, E. C. – Furst, D. E., et al.: Adalimumab,

- a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. *Arthritis Rheum*, 2003, 48, s. 35–45.
- 14 Breedveld, F. C. – Weisman, M. H. – Kavanaugh, A. F., et al.: The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum*, 2006, 54, s. 26–37.
  - 15 van der Heijde, D. – Kivitz, A. – Schiff, H. M., et al.: Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial. *Arthritis Rheum*, 2006, 54, s. 2136–2146.
  - 16 Haibel, H. – Rudwaleit, M. – Listing, J., et al.: Efficacy of adalimumab in the treatment of axial spondyloarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. *Arthritis Rheum*, 2008, 58, s. 1981–1991.
  - 17 Mease, P. J. – Ory, P. – Sharp, J. T., et al.: Adalimumab for long-term treatment of psoriatic arthritis: 2 year data from the adalimumab effectiveness in psoriatic arthritis trial (ADEPT). *Ann Rheum Dis*, 2009, 68, s. 702–709.
  - 18 Weinblatt, M. E. – Kremer, J. M. – Bankhurst, A. D., et al.: A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. *N Engl J Med*, 1999, 340, s. 253–259.
  - 19 Moreland, L. W. – O'Dell, J. R. – Paulus, H. E., et al.: A randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis Trial. *Arthritis Rheum*, 2012, 64, s. 2824–2835.
  - 20 Emery, P. – Breedveld, F. C. – Hall, S., et al.: Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): A randomised, double blind, parallel treatment trial. *Lancet*, 2008, 372, s. 372–382.
  - 21 Braun, J. – van der Horst-Bruinsma, I. E., et al.: Clinical efficacy and safety of etanercept versus sulfasalazine in ankylosing spondylitis patients: A randomized, double blind trial. *Arthritis Rheum*, 2011, 63, s. 1543–1551.
  - 22 Song, I. H. – Hermann, K. G. – Haibel, H., et al.: Consistently good clinical response in patients with early axial spondyloarthritis after 3 years of continuous treatment with etanercept: longterm data of the ESTHER trial. *J Rheumatol*, 2014, 41, s. 2034–2034.
  - 23 Weinblatt, M. E. – Moreland, L. W. – Westhovens, R., et al.: Safety of abatacept administered intravenously in treatment of rheumatoid arthritis: integrated analyses of up to 8 years of treatment from the abatacept clinical program. *J Rheumatol*, 2013, 40, s. 787–797.
  - 24 Flint, J., et al.: BSR and BHPH guideline on prescribing drugs in pregnancy and breastfeeding-Part I: standard and biologic disease modifying anti-rheumatic drugs and corticosteroids. *Rheumatology*, 2016, publikováno online, doi:10.1093/rheumatology/kev404.
  - 25 Fleischmann, R. – Vencovsky, J. – Vollenhoven, R. F., et al.: Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease modifying antirheumatic therapy: The FAST4WARD study. *Ann Rheum Dis*, 2009, 68, s. 805–811.
  - 26 Keystone, E. – Heijde, D. – Mason, D., et al.: Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. *Arthritis Rheum*, 2008, 58, s. 3319–3329.
  - 27 Smolen, J. – Landewe, R. B. – Mease, P., et al.: Efficacy and safety of certolizumab pegol plus methotrexate in active rheumatoid arthritis: the RAPID 2 study. A randomised controlled trial. *Ann Rheum Dis*, 2009, 68, s. 797–804.
  - 28 Weinblatt, M. E. – Fleischmann, R. – Huizenga, T. W., et al.: Efficacy and safety of certolizumab pegol in a broad population of patients with active rheumatoid arthritis: Results from the REALISTIC phase IIIb study. *Rheumatology (Oxford)*, 2012, 51, s. 2204–2214.
  - 29 Sieper, J. – Landewé, R. – Rudwaleit, M., et al.: Effect of certolizumab pegol over 96 weeks in patients with axial spondyloarthritis: Results from a phase 3 randomized trial. *Arthritis Rheumatol*, 2015, 67, s. 668–677, doi: 10.1002/art.38973.
  - 30 Emery, P. – Fleischmann, R. M. – Moreland, L. W., et al.: Golimumab, a human anti-tumor necrosis factor alpha monoclonal antibody, injected subcutaneously every four weeks in methotrexate naive patients with active rheumatoid arthritis: Twenty four week results of a phase III, multicenter, randomized, double-blind, placebo-controlled study of golimumab before methotrexate as first/line therapy for early-onset RA. *Arthritis Rheum*, 2009, 60, s. 2272–2283.
  - 31 Smolen, J. S. – Kay, J. – Doyle, M. K., et al.: Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study) a multicentre, randomised, double blind, placebo controlled phase III study. *Lancet*, 2009, 374, s. 210–221.
  - 32 Pavelka, K.: Komentář ke studii s golimumabem prezentovaným na kongresu EULAR v Paříži. *Farmakoterapie*, 2014, 10, s. 337–338.
  - 33 Braun, J. – Baraliakos, X. – Hermann, K. G., et al.: Golimumab reduces spinal inflammation in ankylosing spondylitis. MRI results of the randomised, placebo-controlled GO-RAISE study. *Ann Rheum Dis*, 2012, 71, s. 878–884.
  - 34 Emery, P. – Fleischmann, R. – Sosnowska, A., et al.: The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. *Arthritis Rheum*, 2006, 54, s. 1390–1400.
  - 35 Keystone, E. – Emery, P. – Peterfy, C. D., et al.: Prevention of joint structural damage at 1 year with rheumatoid arthritis patients with inadequate response to one or more TNF inhibitors (Reflex study). *Ann Rheum Dis*, 2006, 65, s. 58.
  - 36 Emery, P. – Deodhar, A. – Rigby, W. F., et al.: Efficacy and safety of different doses and retreatment of rituximab: a randomised, placebo-controlled trial in patients who are biological naive with active rheumatoid arthritis and an inadequate response to methotrexate (Study Evaluating Rituximab's Efficacy in MTX Inadequate Responders (SERENE)). *Ann Rheum Dis*, 2010, 69, s. 1629–1635.
  - 37 Tak, P. P. – Rigby, W. F. – Rubbert-Roth, A., et al.: Inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. *Ann Rheum Dis*, 2011, 70, s. 39–46.
  - 38 Jones, G. – Sebba, A. – Gu, J., et al.: Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. *Ann Rheum Dis*, 2010, 69, s. 88–96.
  - 39 Maini, R. N. – Taylor, P. C. – Szechinsky, J., et al.: Double-blind randomized controlled clinical trial of the interleukin-6 receptor antagonist, tocilizumab, in European patients with rheumatoid arthritis who had an incomplete response to methotrexate. *Arthritis Rheum*, 2006, 54, s. 2817–2829.
  - 40 Nishimoto, N. – Hashimoto, J. – Miyasaka, N., et al.: Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. *Ann Rheum Dis*, 2007, 66, s. 1162–1170.
  - 41 Smolen, J. S. – Beaulieu, A. – Rubbert-Roth, A., et al.: Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. *Lancet*, 2008, 371, s. 987–997.
  - 42 Genovese, M. C. – McKay, J. D. – Nasonov, E. L., et al.: Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: the tocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. *Arthritis Rheum*, 2008, 58, s. 2968–2980.
  - 43 Emery, P. – Keystone, E. – Tony, H. P., et al.: IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. *Ann Rheum Dis*, 2008, 67, s. 1516–1523.
  - 44 Gabay, C. – Emery, P. – van Vollenhoven, R., et al.: Tocilizumab monotherapy versus adalimumab monotherapy for treatment of rheumatoid arthritis (ADACTA): a randomised, double-blind, controlled phase 4 trial. *Lancet*, 2013, 381, s. 1541–1550.
  - 45 Burmester, G. R. – Rubbert-Roth, A., et al.: A randomised, double-blind, parallel-group study of the safety and efficacy of subcutaneous tocilizumab versus intravenous tocilizumab in combination with traditional disease-modifying antirheumatic drugs in patients with moderate to severe rheumatoid arthritis (SUMMECTA study). *Ann Rheum Dis*, 2014, 73, s. 69–74.
  - 46 Navarra, S. V. – Guzman, R. M. – Gallacher, A. E., et al.: BLISS-52 Study Group. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. *Lancet*, 2011, 377, s. 721–731.
  - 47 Gottlieb, A. – Narang, K.: Ustekinumab in the treatment of psoriatic arthritis: Latest findings and clinical potential. *Ther Adv Musculoskelet Dis*, 2013, 5, s. 277–285.
  - 48 McInnes, I. B., et al.: Secukinumab, a human anti-interleukin 17A monoclonal antibody, in patients with psoriatic arthritis (FUTURE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2015, 386, s. 1137–1146.

## Přehled závažných lékových interakcí antibiotik

PharmDr. Lenka Součková Ph.D. Farmakologický ústav LF MU, Klinika dětské onkologie FN Brno, Výzkumná infrastruktura CZECRIN FN u sv. Anny v Brně

- 1 Hodnocení distribuovaných a vydaných léčivých přípravků za rok 2015. Dostupné z: <http://www.sukl.cz/hodnoceni-distribuovanych-a-vydanych-lecivych-pripravku-za-vyhledano> 19. 10. 2016.
- 2 Guaraldo, L. – Cano, F. G. – Damasceno, G. S., et al.: Inappropriate medication use among the elderly: a systematic review of administrative databases. *BMC Geriatr*, 2011, 11, s. 79.
- 3 Johnell, K. – Klarin, I.: The relationship between number of drugs and potential drug-drug interactions in the elderly. *Drug Safety*, 2007, 30, s. 911–918.
- 4 Köhler, G. I. – Bode-Böger, S. M. – Busse, R., et al.: Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use. *Inte J Clin Pharm Ther*, 2000, 38, s. 504–513.
- 5 Aronson, J. K.: Classifying drug interactions. *British J Clin Pharm*, 2004, 58, s. 343–344.
- 6 Lawrence, A. Trissel; American Pharmacists Association: *Trissel's Stability of Compounded Formulations*. Washington, DC American Pharmacists Assoc, 2005.
- 7 Newton, D. W.: Drug incompatibility chemistry. *Am J Health Syst Pharm*, 2009, 66, s. 348–357.
- 8 Bradley, J. S., et al.: Intravenous ceftriaxone and calcium in the neonate: assessing the risk for cardiopulmonary adverse events. *Pediatrics*, 2009, 123, s. 609–613.
- 9 Dostupné z: <http://www.helapet.co.uk/downloads/>
- 10 Tice, A. D. – Rehm, S. J. – Dalovisio, J. R., et al.: Practice guidelines for outpatient parenteral antimicrobial therapy. *Practice Guidelines for OPAT*, 2004, 38, s. 1651–1672.
- 11 Ghaibi, S., et al.: Light-sensitive injectable prescription drugs. *Hosp Pharm*, 2014, 49, s. 136–163.
- 12 Handbook on Injectable Drugs, 18. vydání, 2015. *Amer Soc of Health-System Pharm*, s. 1280.
- 13 Gahart, B. L. – Nazaréni, A. R.: *Intravenous medications: A handbook for nurses and health professionals*. 29. vydání, St. Louis, 2013. MO, Mosby Elsevier, s. 1252.
- 14 Gin, A. – Dilay, L. – Karlowsky, J. A., et al.: Piperacillin–tazobactam: a  $\beta$ -lactam/ $\beta$ -lactamase inhibitor combination. *Expert review of anti-infective therapy*, 2007, 5, s. 365–383.
- 15 Vijayakumar, A. – Sharon, E. V. – Teena, J., et al.: A clinical study on drug-related problems associated with intravenous drug administration. *J Basic Clin Pharm*, 2014, 5, s. 49–53.
- 16 Marsilio, N. R. – da Silva, D. – Bueno, D.: Drug incompatibilities in the adult intensive care unit of a university hospital. *Revista Brasileira de Terapia Intensiva*, 2016, 28, s. 147–153.
- 17 Giamarellou, H.: Aminoglycosides plus beta-lactams against gram-negative organisms: Evaluation of in vitro synergy and chemical interactions. *Am J Med*, 1986, 80, s. 126–137.
- 18 Uivarosi, V.: Metal complexes of quinolone antibiotics and their applications: an update. *Molecules*, 2013, 18, s. 11153–11197.
- 19 Morran, C., et al.: Brief Report: pharmacokinetics of orally administered ciprofloxacin in abdominal surgery. *Am J Med*, 1989, 87, dopl. 5A, s. 865–885.
- 20 Ellis, R. J. – Mayo, M. S. – Bodensteiner, D. M.: Ciprofloxacin-warfarin coagulopathy: a case series. *Am J Hematol*, 2000, 63, s. 28–31.
- 21 Hines, L. E. – Murphy, J. E.: Potentially harmful drug–drug interactions in the elderly: a review. *Am J Geriatr Pharm*, 2011, 9, s. 364–377.
- 22 Gillum, J. G. – Israel, D. S. – Polk, R. E.: Pharmacokinetic drug interactions with antimicrobial agents. *Clin Pharm*, 1993, 25, s. 450–482.
- 23 Cupp, M. J. – Tracy, T. S.: Cytochrome P450: new nomenclature and clinical implications. *Am Fam Physician*, 1998, 57, s. 107–116.
- 24 Belpaire, F. M. – Bogaert, M. G.: Cytochrome P450: genetic polymorphism and drug interactions. *Acta Clinica Belgica*, 1996, 51, s. 254–260.
- 25 *Lékové interakce antibiotik*. MUDr. Michal Prokeš, Infopharm, Praha. Dostupné z: <http://www.edukafarm.cz/c533>, vyhledáno 16. 10. 2016.
- 26 Novotný, J. – Novotný, M.: Adverse drug reactions to antibiotics and major antibiotic drug interactions. *Gen Physiol Biophys*, 1999, 18, s. 126–139.
- 27 Wu, C. C. – Pai, T. Y. – Hsiao, F. Y., et al.: The effect of different carbapenem antibiotics (ertapenem, imipenem/cilastatin, and meropenem) on serum valproic acid concentrations. *Therapeutic Drug Monitoring*,

- 2016, 38, s. 587–592.
- 28 Westphal, J. F.: Macrolide-induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. *Brit J Clin Pharm*, 2000, 50, s. 285–295.
- 29 Koukalová, L. – Baranová, J. – Anzenbacher, P.: Lékové interakce na úrovni cytochromů P450 – Část I. Interakce na úrovni CYP3A4. *Klin Farmakol Farm*, 2003, 17, s. 151–157.
- 30 Jaehde, U. – Sörgel, F. – Reiter, A., et al.: Effect of probenecid on the distribution and elimination of ciprofloxacin in humans. *Clin Pharm Ther*, 1995, 58, s. 532–541.
- 31 Ko, Y. H. – Song, P. H.: Current updates in pharmacokinetics and pharmacodynamics of fluoroquinolones. *Korean J Urogen Tract Infect Inflamm*, 2015, 10, s. 1–6.
- 32 Groenendal, H. – Ramen, F. H. J.: Methotrexate and trimethoprim-sulphamethoxazole—a potentially hazardous combination. *Clin Exp Derm*, 1990, 15, s. 358–360.
- 33 Ronchera, C. L. – Hernandez, T. – Peris, J. E., et al.: Pharmacokinetic interaction between high-dose methotrexate and amoxicillin. *Ther Drug Monit*, 1993, 15, s. 375–379.
- 34 Watts, C. S. – Sciasci, J. N. – Pauley, J. L., et al.: Prophylactic trimethoprim-sulfamethoxazole does not affect pharmacokinetics or pharmacodynamics of methotrexate. *J Ped Hem Oncol*, 2016, 38, s. 449–452.
- 35 Bamgbola, O.: Review of vancomycin-induced renal toxicity: an update. *Ther Adv Endocrin Metab*, 2016, s. 1–15, doi: 10.1177/2042018816638223.
- 36 Inghammar, M. – Svanström, H. – Melbye, M., et al.: Oral fluoroquinolone use and serious arrhythmia: bi-national cohort study. *BMJ*, 2016, 352, s. i843.
- 37 Shakeri-Nejad, K. – Stahlmann, R.: Drug interactions during therapy with three major groups of antimicrobial agents. *Expert Opin Pharm*, 2006, 7, s. 639–651.

## Noxafil 300 mg koncentrát pro infuzní roztok – lékový profil

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 Herbrecht, R.: Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. *Int J Clin Pract*, 2004, 58, s. 612–624.
- 2 Keating, G. M.: Posaconazole. *Drugs*, 2005, 65, s. 1553–1567.
- 3 Conte, J. E. Jr. – DeVoe, C. – Little, E., et al.: Steady-state intrapulmonary pharmacokinetics and pharmacodynamics of posaconazole in lung transplant recipients. *Antimicrob Agents Chemother*, 2010, 54, s. 3609–3613.
- 4 Tobon, A. M. – Arango, M. – Fernandez, D., et al.: Mucormycosis (zygomycosis) in a heart-kidney transplant recipient: recovery after posaconazole therapy. *Clin Infect Dis*, 2003, 36, s. 1488–1491.
- 5 Sponsel, W. E. – Graybill, J. R. – Nevarez, H. L. – Dang, D.: Ocular and systemic posaconazole (SCH-56592) treatment of invasive *Fusarium solani* keratitis and endophthalmitis. *Br J Ophthalmol*, 2002, 86, s. 829–830.
- 6 Kersemaekers, W. M. – van Iersel, T. – Nassander, U., et al.: Pharmacokinetics and safety study of posaconazole intravenous solution administered peripherally to healthy subjects. *Antimicrob Agents Chemother*, 2015, 59, s. 1246–1251.
- 7 Herbrecht, R.: Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. *Int J Clin Pract*, 2004, 58, s. 612–624.
- 8 Ezzet, F. – Wexler, D. – Courtney, R., et al.: Oral bioavailability of posaconazole in fasted healthy subjects: comparison between three regimens and basis for clinical dosage recommendations. *Clin Pharmacokinet*, 2005, 44, s. 211–220.
- 9 Courtney, R. – Pai, S. – Laughlin, M., et al.: Pharmacokinetics, safety, and tolerability of oral posaconazole administered in single and multiple doses in healthy adults. *Antimicrob Agents Chemother*, 2003, 47, s. 2788–2795.
- 10 Krishna, G. – Ma, L. – Martinho, M. – O'Mara, E.: Single-dose phase I study to evaluate the pharmacokinetics of posaconazole in new tablet and capsule formulations relative to oral suspension. *Antimicrob Agents Chemother*, 2012, 56, s. 4196–4201.
- 11 Maertens, J. – Cornely, O. A. – Ullmann, A. J., et al.: Phase 1B study of the pharmacokinetics and safety of posaconazole intravenous solution in patients at risk for invasive fungal disease. *Antimicrob Agents Chemother*, 2014, 58, s. 3610–3617.
- 12 Jeong, W. – Haywood, P. – Shanmuganathan, N., et al.: Safety, clinical effectiveness and trough plasma concentrations of intravenous posaconazole in patients with haematological malignancies and/or undergoing allogeneic haematopoietic stem cell transplantation: off-trial experience. *J Antimicrob Chemother*, 2016, v tisku.
- 13 Guarascio, A. J. – Slain, D.: Review of the new delayed-release oral tablet and intravenous dosage forms of posaconazole. *Pharmacotherapy*, 2015, 35, s. 208–219.
- 14 Wexler, D. – Courtney, R. – Richards, W., et al.: Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. *Eur J Pharm Sci*, 2004, 21, s. 645–653.
- 15 Kraft, W. K. – Chány, P. S. – van Iersel, M. L., et al.: Posaconazole tablet pharmacokinetics: lack of effect of concomitant medications altering gastric pH and gastric motility in healthy subjects. *Antimicrob Agents Chemother*, 2014, 58, s. 4020–4025.

## Má antiangiogenní léčba u karcinomu prsu význam?

MUDr. Tomáš Svoboda, Ph.D. Onkologická a radioterapeutická klinika FN, Plzeň

- 1 Cameron, D. – Brown, J. – Dent, R., et al.: Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial. *Lancet Oncol*, 2013, 14, s. 933–942.
- 2 Slamon, D. J. – Swain, S. M. – Buysse, M., et al.: Primary results from BETH, a phase 3 controlled study of adjuvant chemotherapy and trastuzumab ± bevacizumab in patients with HER2-positive, node-positive or high risk node-negative breast cancer. *SABCS*, 2013, abstrakt S1–03.
- 3 Miller, K. – O'Neill, A. M. – Dang, Ch. T., et al.: Bevacizumab (Bv) in the adjuvant treatment of HER2-negative breast cancer: Final results from Eastern Cooperative Oncology Group E5103. *ASCO* 2014. *J Clin Oncol*, 2014, 32, s. 5, dopl., abstrakt 500.
- 4 von Minckwitz, G. – Schneeweiss, A. – Loibl, S., et al.: Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. *Lancet Oncol*, 2014, 15, s. 747–756.
- 5 Delaloge, S. – Perol, D. – Brain, E., et al.: Overall survival of patients with HER2-negative metastatic breast cancer treated with a first-line paclitaxel with or without bevacizumab in real-life setting: results of a multicenter national observational study. *ASCO* 2016. *J Clin Oncol*, 2016, 34, dopl., abstrakt 1013.

## Palbociclib v léčbě metastatického karcinomu prsu

MUDr. Katarína Petráková, Ph.D. Klinika komplexní onkologické péče MOÚ, Brno

- 1 Thangavel, C. – Dean, J. L. – Ertel, A., et al.: Therapeutically activating RB: reestablishing cell cycle control in endocrinotherapy-resistant breast cancer. *Endocr Relat Cancer*, 2011, 18, s. 333–345.
- 2 Murphy, C. G. – Dickler, M. N.: The role of CDK4/6 inhibition in breast cancer. *Oncologist*, 2015, 20, s. 483–490.
- 3 Flaherty, K. T. – Lorusso, P. M. – Demichele, A., et al.: Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. *Clin Cancer Res*, 2012, 18, s. 568–576.
- 4 Finn, R. S. – Crown, J. P. – Lang, I., et al.: The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study. *Lancet Oncol*, 2015, 16, s. 25–35.
- 5 Finn, R. S. – Crown, J. P. – Ettl, J., et al.: Efficacy and safety of palbociclib in combination with letrozole as first-line treatment of ER-positive, HER2-negative, advanced breast cancer: expanded analyses of subgroups from the randomized pivotal trial PALOMA-1/TRIO-18. *Breast Cancer Res*, 2016, 18, s. 67.
- 6 Cristofanilli, M. – Turner, N. C. – Bondarenko, I., et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. *Lancet Oncol*, 2016, 17, s. 425–439.
- 7 Verma, S. – Bartlett, C. H. – Schnell, P., et al.: Palbociclib in combination with fulvestrant in women with hormone receptor-positive/HER2-negative advanced metastatic breast cancer: detailed safety analysis from a multicenter, randomized, placebo-controlled, phase III study (PALOMA-3). *Oncologist*, 2016, 21, s. 1165–1175.
- 8 Ibrance – Souhmi údaj o přípravku (SPC).

# Imunoterapie nádorových onemocnění z pohledu imunologa

doc. MUDr. Eva Závadová, CSc. | prof. MUDr. Terezie Fučíková, DrSc. | MUDr. Jan Špaček | MUDr. Michal Vočka | doc. MUDr. Bohuslav Konopásek, CSc. Onkologická klinika 1. LF UK a VFN, Praha  
PharmDr. Irena Netíková, Ph.D. Oddělení klinické farmakologie a farmacie VFN, Praha

- 1 Galon, J. – Závadová, E. – Mlecnik, B., et al.: Towards the introduction of the 'Immunoscore' in the classification of malignant tumours. *J Pathol*, 2014, 232, s. 199–209.
- 2 Fučíková, T. – Závadová, E. – Krejsek, J. – Svoboda, J.: Hodnocení imunitní odpovědi u pacientů s nádorovým onemocněním. In: *Onkologická imunologie*, Praha, 2015.
- 3 Postow, M. A. – Callahan, M. K. – Barker, C. A., et al.: Immunologic correlates of the abscopal effect in a patient with melanoma. *N Engl J Med*, 2012, 366, s. 925–931.
- 4 Weber, J. S. – Thompson, J. A. – Hamid, O., et al.: A randomized, double blind, placebo-controlled, phase 2 study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage 3 or 4 melanoma. *Clin Cancer Res*, 2009, 15, s. 5591–5598.
- 5 Wolchok, J. D. – Hoos, A. – O'Day, S., et al.: Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. *Clin Cancer Res*, 2009, 15, s. 7412–7420.
- 6 Couzin-Frankel, J.: Cancer Immunotherapy. *Science*, 2013, 342, s. 1432–1433.

## Farmakologická léčba kašle

MUDr. Stanislav Konštický, CSc. Lékařská fakulta Hradec Králové a Lázně Bělohrad

- 1 Classen, M., et al.: *Diferenciální diagnóza ve schématech*. Grada Publishing, Praha, 2003.
- 2 Novák, I.: *Pediatric*. In: Pokorný, J., et al.: *Urgentní medicína*. Galén, 2004, Praha, s. 298–464.
- 3 Kruse, K., Linhart, J.: *Pediatric*. In: Schettler, G., et al.: *Repetitorium praktického lékaře*. Galén, Praha, 1995, s. 442–444.
- 4 Ulmer, T. – Votava, V.: *Pneumologie*. In: Schettler, G., et al.: *Repetitorium praktického lékaře*. Galén, Praha, 1995, s. 949–950.
- 5 Čáp, P. – Vondra, V.: *Kašel, příčiny, diagnostika a léčba*. Vltavín, Praha, 2000.

Další literatura u autora

## Nová naděje pro pacienty s Crohnovou chorobou: ustekinumab, monoklonální protilátka anti-IL-12/23

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Sandborn, W. J. – Feagan, B. G. – Rutgeerts, P., et al.: Vedolizumab as induction and maintenance therapy for Crohn's disease. *N Engl J Med*, 2013, 369, s. 711–721.
- 2 Sandborn, W. J. – Gasink, C. – Gao, L. L., et al.: Ustekinumab induction and maintenance therapy in refractory Crohn's disease. *N Engl J Med*, 2012, 367, s. 1519–1528.
- 3 Toedter, G. P. – Blank, M. – Lang, Y., et al.: Relationship of C-reactive protein with clinical response after therapy with ustekinumab in Crohn's disease. *Am J Gastroenterol*, 2009, 104, s. 2768–2773.
- 4 Simon, E. G. – Samuel, S. – Ghosh, S., et al.: Ustekinumab: a novel therapeutic option in Crohn's disease. *Expert Opin Biol Ther*, 2016, 16, s. 1065–1074.

## Fixní kombinace naltrexon/bupropion

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie, 3. LF UK, Praha

- 1 Christou, G. A. – Kiortsis, D. N.: The efficacy and safety of the naltrexone/bupropion combination for the treatment of obesity: an update. *Hormones Athens*, 2015, 14, s. 370–375.
- 2 Billes, S. K. – Sinnayah, P. – Cowley, M. A.: Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. *Pharmacol Res*, 2014, 84, s. 1–11.
- 3 Greenway, F. L. – Fujioka, K. – Plodkowski, R. A., et al.: Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. *Lancet*, 2010, 376, s. 595–605.
- 4 Apovian, C. M. – Aronne, L. – Rubino, D., et al.: A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). *Obesity Silver Spring*, 2013, 21, s. 935–943.
- 5 Wadden, T. A. – Foreyt, J. P. – Foster, G. D., et al.: Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. *Obesity Silver Spring*, 2011, 19, s. 110–120.
- 6 Hollander, P. – Gusta, A. K. – Plodkowski, R., et al.: Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. *Diabetes Care*, 2013, 36, s. 4022–4029.
- 7 Kolotkin, R. L. – Chen, S. – Klassen, P., et al.: Patient-reported quality of life in a randomized placebo-controlled trial of naltrexone/bupropion for obesity. *Clin Obes*, 2015, 5, s. 237–244.
- 8 McElroy, S. L. – Guerdjikova, A. I. – Kim, D. D., et al.: Naltrexone/bupropion combination therapy in overweight or obese patients with major depressive disorder: results of a pilot study. *Prim Care Companion CNS Disord*, 2013, 15, pii: PCC.12m01494, doi: 10.4088/PCC.12m01494.
- 9 Saunders, K. H. – Igel, L. I. – Aronne, L. J.: An update on naltrexone/bupropion extended-release in the treatment of obesity. *Expert Opin Pharmacother*, 2016.
- 10 Tek, C.: Naltrexone HCl/bupropion HCl for chronic weight management in obese adults: patient selection and perspectives. *Patient Prefer Adherence*, 2016, 10, s. 751–759.
- 11 Halpern, B. – Mancini, M. C.: Safety assessment of combination therapies in the treatment of obesity: Focus on naltrexone/bupropion extended release and phentermine-topiramate extended release. *Expert Opin Drug Saf*, 2016.
- 12 Nissen, S. E. – Wolski, K. E. – Prcela, L., et al.: Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. *JAMA*, 2016, 315, s. 990–1004.



# Terapeutický potenciál fixní kombinace grazoprevir/elbasvir v léčbě hepatitidy C

MUDr. Jiří Slíva, Ph.D. Ústav farmakologie 3. LF UK, Praha

- 1 **Marinaki, S. – Boletka, J. N. – Sakellariou, S., et al.:** Hepatitis C in hemodialysis patients. *World J Hepatol*, 2015, 7, s. 548–558.
- 2 **Fabrizi, F. – Dixit, V. – Mensa, P.:** Impact of hepatitis C on survival in dialysis patients: a link with cardiovascular mortality? *J Viral Hepat*, 2012, 19, s. 601–607.
- 3 **Karbone, M. – Mutimer, D. – Neuberger, J.:** Hepatitis C virus and non-liver solid organ transplantation. *Transplantation*, 2013, 95, s. 779–786.
- 4 **Kratiny, G. M.:** Elbasvir/grazoprevir: first global approval. *Drugs*, 2016, 76, s. 617–624.
- 5 **Sulkowski, M. – Hezode, C. – Gerstoft, J., et al.:** Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet*, 2015, 385, s. 1087–1097.
- 6 **Lawitz, E. – Gane, E. – Pearlman, B., et al.:** Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. *Lancet*, 2015, 385, s. 1075–1086.
- 7 **Forns, X. – Gordon, S. C. – Zuckerman, E., et al.:** Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent. *J Hepatol*, 2015, 63, s. 564–572.
- 8 **Buti, M. – Gordon, S. C. – Zuckerman, E., et al.:** Grazoprevir, elbasvir, and ribavirin for chronic hepatitis C virus genotype 1 infection after failure of pegylated interferon and ribavirin with an earlier-generation protease inhibitor: final 24-week results from C-SALVAGE. *Clin Infect Dis*, 2016, 62, s. 32–36.
- 9 **Teutem, S. – Ghalib, R. – Reddy, K. R., et al.:** Grazoprevir-elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. *Ann Intern Med*, 2015, 163, s. 1–13.
- 10 **Rockstroh, J. K. – Nelson, M. – Katlama, C., et al.:** Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. *Lancet HIV*, 2015, 2, s. e319–e327.
- 11 **Roth, D. – Nelson, D. R. – Bruchfeld, A., et al.:** Grazoprevir plus elbasvir in treatment-naïve and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study. *Lancet*, 2015, 386, s. 1537–1545.